Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

先声药业 Simcere

Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

PROFIT ALERT

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors ("**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended June 30, 2021, it is expected that the Group will record a profit attributable to equity shareholders of the Company of approximately RMB538 million to RMB578 million for the six months ended June 30, 2021, representing an increase of approximately RMB352 million to RMB392 million, or approximately 190% to 211%, as compared to the profit attributable to equity shareholders of the Company for the same period last year. Such increase was mainly attributable to: (i) the rapid increase in revenue from Sanbexin (edaravone and dexborneol concentrated solution for injection), a Class I innovative drug developed originally which was launched in July 2020; (ii) a gain (before tax) of approximately RMB399 million recorded by the Group from the disposal of its entire equity interest in Simgene Group Limited in the first half of 2021; (iii) an increase in the research and development costs of approximately RMB170 million as compared to that for the same period last year for rapid advancement of the clinical pipeline in the first half of 2021; and (iv) an increase in the marketing expenses of approximately RMB200 million as compared to that for the same period last year for accelerating the efficient promotion of the newly launched products, such as the innovative drug Sanbexin.

The Company is still in the process of finalising the interim results of the Group for the six months ended June 30, 2021. The information contained in this announcement is based solely on the preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended June 30, 2021 and is subject to finalisation and other potential adjustments, if any, and has not been reviewed or confirmed by the Group's auditors or the Audit Committee of the Board. Shareholders and potential investors of the Company should refer to the Group's interim results announcement for the six months ended June 30, 2021, which is expected to be published by the end of August 2021.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, August 2, 2021

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.